212 related articles for article (PubMed ID: 26275417)
1. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A; Jones A; Joe H; Heap L; Smith MJ; Wallace AJ; Halliday D; Parry A; Taylor A; Raymond L; Shaw A; Afridi S; Obholzer R; Axon P; King AT; ; Friedman JM; Evans DG
J Med Genet; 2015 Oct; 52(10):699-705. PubMed ID: 26275417
[TBL] [Abstract][Full Text] [Related]
2. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2).
Zhao Y; Kumar RA; Baser ME; Evans DG; Wallace A; Kluwe L; Mautner VF; Parry DM; Rouleau GA; Joe H; Friedman JM
Genet Epidemiol; 2002 Oct; 23(3):245-59. PubMed ID: 12384977
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 2 (NF2): a clinical and molecular review.
Evans DG
Orphanet J Rare Dis; 2009 Jun; 4():16. PubMed ID: 19545378
[TBL] [Abstract][Full Text] [Related]
4. In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2: From Genotype to Phenotype.
Heineman TE; Evans DG; Campagne F; Selesnick SH
Otol Neurotol; 2015 Jun; 36(5):908-14. PubMed ID: 25931164
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.
Kluwe L; MacCollin M; Tatagiba M; Thomas S; Hazim W; Haase W; Mautner VF
Am J Med Genet; 1998 May; 77(3):228-33. PubMed ID: 9605590
[TBL] [Abstract][Full Text] [Related]
6. Predictors of the risk of mortality in neurofibromatosis 2.
Baser ME; Friedman JM; Aeschliman D; Joe H; Wallace AJ; Ramsden RT; Evans DG
Am J Hum Genet; 2002 Oct; 71(4):715-23. PubMed ID: 12235555
[TBL] [Abstract][Full Text] [Related]
7. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.
Kluwe L; Bayer S; Baser ME; Hazim W; Haase W; Fünsterer C; Mautner VF
Hum Genet; 1996 Nov; 98(5):534-8. PubMed ID: 8882871
[TBL] [Abstract][Full Text] [Related]
8. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
9. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.
Baser ME; Kuramoto L; Joe H; Friedman JM; Wallace AJ; Gillespie JE; Ramsden RT; Evans DG
Am J Hum Genet; 2004 Aug; 75(2):231-9. PubMed ID: 15190457
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
11. Further genotype--phenotype correlations in neurofibromatosis 2.
Selvanathan SK; Shenton A; Ferner R; Wallace AJ; Huson SM; Ramsden RT; Evans DG
Clin Genet; 2010 Feb; 77(2):163-70. PubMed ID: 19968670
[TBL] [Abstract][Full Text] [Related]
12. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG
J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.
Mohyuddin A; Neary WJ; Wallace A; Wu CL; Purcell S; Reid H; Ramsden RT; Read A; Black G; Evans DG
J Med Genet; 2002 May; 39(5):315-22. PubMed ID: 12011146
[TBL] [Abstract][Full Text] [Related]
14. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.
Evans DG; Trueman L; Wallace A; Collins S; Strachan T
J Med Genet; 1998 Jun; 35(6):450-5. PubMed ID: 9643284
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II].
Evans DG
Genet Med; 2009 Sep; 11(9):599-610. PubMed ID: 19652604
[TBL] [Abstract][Full Text] [Related]
16. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas.
Hung G; Faudoa R; Baser ME; Xue Z; Kluwe L; Slattery W; Brackman D; Lim D
Cancer Genet Cytogenet; 2000 Apr; 118(2):167-8. PubMed ID: 10748301
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of the NF2 gene in Korean patients with neurofibromatosis type 2: a report of four novel mutations.
Seong MW; Yeo IK; Cho SI; Park CK; Kim SK; Paek SH; Kim DG; Jung HW; Park H; Kim SY; Kim JY; Park SS
Korean J Lab Med; 2010 Apr; 30(2):190-4. PubMed ID: 20445339
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene.
Sestini R; Vivarelli R; Balestri P; Ammannati F; Montali E; Papi L
Hum Genet; 2000 Oct; 107(4):366-71. PubMed ID: 11129337
[TBL] [Abstract][Full Text] [Related]
20. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
